Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Healius Limited ( (AU:HLS) ) has shared an update.
Healius has disclosed a change in the interests of non-executive director Katherine Ostin, following on-market purchases of additional fully paid ordinary shares in the company. Ostin acquired 16,264 shares at an average price of $0.6148 per share through trades conducted on 6 and 9 March 2026.
As a result of these transactions, Ostin’s indirect holding increased to 41,343 fully paid ordinary shares, while her direct holding remained at 21,779 shares, alongside 45,955 share rights held indirectly. The company noted that no related contracts were affected and confirmed the trades did not occur during a closed trading period, indicating compliance with Healius’ governance and disclosure requirements.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company that operates in the medical services sector, with activities typically spanning pathology, diagnostic imaging and related healthcare services. The company focuses on providing clinical services to patients and referrers across Australia through a network-based operating model.
Average Trading Volume: 2,777,193
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$442.9M
Learn more about HLS stock on TipRanks’ Stock Analysis page.